TP508 (Chrysalin™, rusalatide acetate)
Acute Respiratory Distress Syndrome (ARDS) from COVID-19 and non-COVID causes (infection, inflammation, traumatic injury)
Key Facts
About Chrysalis BioTherapeutics
Chrysalis BioTherapeutics is a privately held, clinical-stage biotech focused on developing regenerative peptide therapeutics that mimic the body's natural repair signals. Founded in 2012 and based in Galveston, Texas, the company has leveraged over $30 million in non-dilutive funding from NIH and BARDA to build a diverse pipeline targeting acute respiratory distress syndrome (ARDS) and radiation exposure. Its unique business model reduces investor risk by using government grants for technology validation and key development programs, while pursuing investment for clinical trials in ARDS and other indications.
View full company profileAbout Chrysalis BioTherapeutics
Chrysalis BioTherapeutics is a privately held, clinical-stage biotech focused on developing regenerative peptide therapeutics that mimic the body's natural repair signals. Founded in 2012 and based in Galveston, Texas, the company has leveraged over $30 million in non-dilutive funding from NIH and BARDA to build a diverse pipeline targeting acute respiratory distress syndrome (ARDS) and radiation exposure. Its unique business model reduces investor risk by using government grants for technology validation and key development programs, while pursuing investment for clinical trials in ARDS and other indications.
View full company profileAbout Chrysalis BioTherapeutics
Chrysalis BioTherapeutics is a privately held, clinical-stage biotech focused on developing regenerative peptide therapeutics that mimic the body's natural repair signals. Founded in 2012 and based in Galveston, Texas, the company has leveraged over $30 million in non-dilutive funding from NIH and BARDA to build a diverse pipeline targeting acute respiratory distress syndrome (ARDS) and radiation exposure. Its unique business model reduces investor risk by using government grants for technology validation and key development programs, while pursuing investment for clinical trials in ARDS and other indications.
View full company profileAbout Chrysalis BioTherapeutics
Chrysalis BioTherapeutics is a privately held, clinical-stage biotech focused on developing regenerative peptide therapeutics that mimic the body's natural repair signals. Founded in 2012 and based in Galveston, Texas, the company has leveraged over $30 million in non-dilutive funding from NIH and BARDA to build a diverse pipeline targeting acute respiratory distress syndrome (ARDS) and radiation exposure. Its unique business model reduces investor risk by using government grants for technology validation and key development programs, while pursuing investment for clinical trials in ARDS and other indications.
View full company profileAbout Chrysalis BioTherapeutics
Chrysalis BioTherapeutics is a privately held, clinical-stage biotech focused on developing regenerative peptide therapeutics that mimic the body's natural repair signals. Founded in 2012 and based in Galveston, Texas, the company has leveraged over $30 million in non-dilutive funding from NIH and BARDA to build a diverse pipeline targeting acute respiratory distress syndrome (ARDS) and radiation exposure. Its unique business model reduces investor risk by using government grants for technology validation and key development programs, while pursuing investment for clinical trials in ARDS and other indications.
View full company profile